| Literature DB >> 35073730 |
Vanessa Santos1, Cláudia Freitas1,2, Maria Go Fernandes1,2,3,4, Catarina Sousa1, Cristina Reboredo5, Natália Cruz-Martins2,3, Joaquín Mosquera5, Venceslau Hespanhol1,2,3,4, Rosário Campelo5.
Abstract
Liquid biopsies have gained an increasing interest in the last years among medical and scientific communities. Indeed, the value of liquid effusions, while less invasive and more accurate techniques, has been markedly highlighted. Peripheral blood comprises the most often analyzed sample, but recent evidences have pointed out the huge importance of other bodily fluids, including pleural and peritoneal fluids, urine, saliva and cerebrospinal fluid in the detection and monitoring of different tumor types. In face to these advances, this review aims to provide an overview of the value of tumor-associated mutations, detectable in different effusions, and how they can be used in clinical practice, namely in prognosis assessment and early disease and minimal disease recurrence detection, and in predicting the treatment response or acquired-resistance development.Entities:
Keywords: bodily fluids; cancer biomarkers; cancer monitoring; liquid biopsy; tumors
Mesh:
Substances:
Year: 2022 PMID: 35073730 DOI: 10.2217/bmm-2021-0370
Source DB: PubMed Journal: Biomark Med ISSN: 1752-0363 Impact factor: 2.851